Plasma Cardiac Myosin Binding Protein C and Serum NT pro BNP levels in Children with Congestive Heart Failure

Yıl 2025, Cilt: 5 Sayı: 13, 77 - 82, 11.06.2025

Damla Erden , Cemşit Karakurt , Mehmet Çağatay Taşkapan , Özlem Elkıran , Harika Gözükara Bağ

https://doi.org/10.54270/atljm.2025.83

Öz

Heart failure (HF) is a progressive clinical and pathophysiological syndrome brought on by cardiovascular or non-cardiovascular causes and accompanied by symptoms such as edema, respiratory distress, growth retardation, exercise intolerance, circulatory, neurohormonal and molecular disorders. Natriuretic peptides and cardiac troponins are the most used cardiovascular biomarkers for diagnosis and prognosis of HF. Many other biomarkers related to diagnosis, prognosis and risk classification in HF have also been identified.
In this study, we aimed to investigate whether the prognostic value of the cardiac myosin binding protein-C (cMyBP-C) is a possible new biomarker that can be used by the clinician while evaluating newly diagnosed HF in children. This is a prospective case-control study involving 24 children with congestive heart failure (CHF) and 30 healthy children. After taking a medical history and physical examination, patients were evaluated by electrocardiogram, telecardiography and echocardiography, and a modified Ross scoring was performed. Plasma cMyBP-C and other biomarker N-terminal pro-natriuretic peptide (NT-proBNP) values, routine blood tests, liver enzymes were measured during admission. The mean cMyBP-C (ng / ml) plasma level of the patient group was 1.55 ng / ml (0.1-9.4) and the control group, 0.1 ng / ml (0.3-1) (p <0.01). After an evaluation of the etiological investigation, the mean plasma cMyBP-C level detected in the myocarditis group was 1.9 ng / ml (0.1-3.1). Accordingly, the mean value of cMyBP-C in the patient group was significantly higher than the control group and the highest in the acute myocarditis group (p <0.01). CMyBP-C may be a new useful diagnostic and prognostic biomarker in children with acute HF.

Anahtar Kelimeler

Heart failure, children, NT-proBNP, cardiac myosin binding protein C

PLASMA CARDIAC MYOSIN BINDING PROTEIN C AND SERUM NT PRO BNP LEVELS IN CHILDREN WITH CONGESTIVE HEART FAILURE

Öz

Heart failure (HF) is a progressive clinical and pathophysiological syndrome brought on by cardiovascular or non-cardiovascular causes and accompanied by symptoms such as edema, respiratory distress, growth retardation, exercise intolerance, circulatory, neurohormonal and molecular disorders. Natriuretic peptides and cardiac troponins are the most used cardiovascular biomarkers for diagnosis and prognosis of HF. Many other biomarkers related to diagnosis, prognosis and risk classification in HF have also been identified.
In this study, we aimed to investigate whether the prognostic value of the cardiac myosin binding protein-C (cMyBP-C) is a possible new biomarker that can be used by the clinician while evaluating newly diagnosed HF in children. This is a prospective case-control study involving 24 children with congestive heart failure (CHF) and 30 healthy children. After taking a medical history and physical examination, patients were evaluated by electrocardiogram, telecardiography and echocardiography, and a modified Ross scoring was performed. Plasma cMyBP-C and other biomarker N-terminal pro-natriuretic peptide (NT-proBNP) values, routine blood tests, liver enzymes were measured during admission. The mean cMyBP-C (ng / ml) plasma level of the patient group was 1.55 ng / ml (0.1-9.4) and the control group, 0.1 ng / ml (0.3-1) (p <0.01). After an evaluation of the etiological investigation, the mean plasma cMyBP-C level detected in the myocarditis group was 1.9 ng / ml (0.1-3.1). Accordingly, the mean value of cMyBP-C in the patient group was significantly higher than the control group and the highest in the acute myocarditis group (p <0.01). CMyBP-C may be a new useful diagnostic and prognostic biomarker in children with acute HF.

Anahtar Kelimeler

Heart failure, children, NT-proBNP, cardiac myosin binding protein C

Kaynakça

• Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.
• Howlett JG, McKelvie RS, Arnold JMO, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol. 2009;25(2):85–105.
• Hickman PE, Potter JM. New cardiac markers. Aust Prescr. 2003; 26:88–90
• Cohen-Solal A, Laribi S, Ishihara S, Vergaro G, Baudet M, Logeart D, Mebazaa A, Gayat E, Vodovar N, Pascual-Figal DA, Seronde MF. Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. Arch Cardiovasc Dis. 2015; 108:64–74
• Carrier L, Bonne G, Bährend E, Yu B, Richard P, Niel F, Hainque B, Cruaud C, Gary F, Labeit S, Bouhour JB, Dubourg O, Desnos M, Hagège AA, Trent RJ, Komajda M, Fiszman M, Schwartz K. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy, Circ Res. 1997; 80(3): 427-34.
• Govindan S, McElligott A, Muthusamy S, Nair N, Barefield D, Martin JL, Gongora E, Greis KD, Luther PK, Winegrad S, Henderson KK, Sadayappan S., Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J Mol Cell Cardiol. 2012;52(1):154-64.
• Govindan S, Kuster D.W.D, Lin B, Kahn D.J, Jeske W.P, Walenga J.M, Leya F, Hoppensteadt D, Fareed J and Sadayappan S. Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction. Am J Cardiovasc Dis. 2013;3(2):60-70.
• Schulte C, Barwari T, Joshi A, Theofilatos K, Zampetaki A, Barallobre-Barreiro J, Singh B, Sorensen N, Neumann JT, Zeller T, Westermann D. Comparative Analysis of Circulating Non-Coding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury. Circulation research. 2019; 125(3):328–40.
• Ross RD. The Ross Classification for Heart Failure in Children After 25 years: A Review and an Age-Stratified Revision. Pediatr Cardiol. 2012;33:1295-300.
• Kantor PF, Lougheed J, Dancea A, et al. Children’s Heart Failure Study Group. Presentation, Diagnosis, and Medical Management of Heart Failure in Children: Canadian Cardiovascular Society Guidelines. Can J Cardiol. 2013;29(12):1535-52.
• Mangat J, Carter C, Riley G, Burch M. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure. Eur J Heart Fail. 2009;11(1):48–52.
• Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation. 2006;114(10):1063–9.
• Iwanaga Y, Miyazaki S. Heart failure, chronic kidney disease, and biomarkers. Circulation Journal. 2010;74(7):1274–82.
• Shah RV, James L, Januzzi Jr James L. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep. 2010;7:9–14.
• Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50: 1054–60.
• Lok DJA, van de Meer P, Bruggink-André de la Porte PW, et al. Clin Res Cardiol. 2010;99:323–8.
• Razzaque MA, Gupta M, Osinska H, Gulick J, Blaxall BC, Robbins J. An endogenously fragment of the cardiac myosin-binding protein C is pathogenic and can lead to heart failure. Circ Res. 2013; 113(5):553–561
• El Amrousy D, Hodeib H, Suliman G, Hablas N, Salama ER, Esam A. Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure. Pediatric Cardiology. 2016; 38(2), 418–424.
• Chen XJ, Zhang W, Bian ZP , Wu HF, Shao YF, Zhang JN, Zhao S. Cardiac Myosin-Binding Protein C Release Profile After Cardiac Surgery in Intensive Care Unit. Ann Thorac Surg. 2019;108(4):1195-201.
• Jeong EM, Zhou L, Xie A, LiuM, ZhouA, LiuH, LiuD, ShiG, Dudley S. Plasma Cardiac Myosin Binding Protein-C May be a Novel Biomarker for Heart Failure. Heart failure and cardiomyopathies. JACC. 2015;65(10S):993-1009